Skip to search formSkip to main contentSkip to account menu

brentuximab vedotin

Known as: CAC10-1006, cAC10-vcMMAE 
An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab… 
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (2)

AdcetrisSGN-35

Broader (1)

Immunoconjugates
NCIt Antineoplastic Agent TerminologyTumor Necrosis Factor Receptor Superfamily Member 8, humanbrentuximab vedotin 50 MG Injection [Adcetris]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy (ICE) before Autologous Transplantation. Final Analysis of Phase II Study
Introduction: About 10-15% of patients with localized and 25-30% with disseminated classical HL failed to respond or relapse… 
2016
2016
Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A…
Introduction: 30% of Hodgkin Lymphoma (HL) patients are refractory or relapse (RR) after first line therapy. Salvage chemotherapy… 
2016
2016
Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program
Brentuximab vedotin was reported to be effective and safe against refractory/relapsed Hodgkin lymphoma in cohorts of between 12… 
2014
2014
Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy
Background Patients (pts) with Hodgkin lymphoma (HL) who have relapsed/refractory disease after frontline therapy typically… 
Highly Cited
2013
Highly Cited
2013
Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center
The CD30-targeted agent brentuximab vedotin has shown impressive activity in relapsed/refractory Hodgkin lymphoma and anaplastic… 
Highly Cited
2013
Highly Cited
2013
Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma
Abstract Only limited data are available on the role of brentuximab vedotin (SGN-35) in transplant-naive relapsed or refractory… 
Review
2012
Review
2012
Brentuximab vedotin in Hodgkin's lymphoma
Introduction: Monoclonal antibodies (mAbs) directed against antigens expressed by tumor cells have become an effective… 
Review
2012
Review
2012
Brentuximab vedotin in systemic T-cell lymphoma
Introduction: Brentuximab vedotin is an antibody–drug conjugate which consists of the anti-CD30 monoclonal antibody cAC10… 
Highly Cited
2010
Highly Cited
2010
Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
Glembatumumab vedotin (CR-011-vc-MMAE) is a mAb-drug conjugate being developed by Celldex Therapeutics Inc for the treatment of… 
2010
2010
Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Abstract 961 Background: Systemic anaplastic large cell lymphoma (sALCL) is a CD30-expressing malignancy comprising approximately… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)